Information sharing - the most valuable benefit expected from serialization?
NEXUS 17 attendees claim the greatest serialization challenge thus far has been line vendors’ inability to deliver a solution on time and within scope.
TraceLink has announced new industry findings from its annual conference, NEXUS 17. Interactive polling results indicated that the majority of pharmaceutical supply chain professionals (78% of attendees), believe that end-to-end visibility of pharmaceutical products in the supply chain is achievable within the next 5 years, with information sharing between trading partners cited as one of the most valuable business benefits.
At NEXUS 17 in Barcelona earlier this month, TraceLink introduced its strategy for leveraging the industry’s only digital supply chain network to facilitate a new era of real-time information sharing, addressing a critical information gap that has existed for decades between pharmaceutical companies, pharmacists and patients. The first application unveiled within this road map, the Pharmacy Compliance and Digital Information Platform, enables any EU pharmacy to easily comply with verification and decommissioning requirements under the Falsified Medicines Directive (FMD), while simultaneously delivering a real-time dashboard for insights into pharmacy operations and enabling a direct communication channel from the pharmaceutical manufacturer to the pharmacy.
NEXUS 17 drew more than 200 pharmaceutical supply chain professionals and business leaders, representing over 120 unique companies from 21 different countries. The conference included educational content from 30 speakers, including esteemed keynote speaker, Dr Bertalan Mesko – “The Medical Futurist” and experts from Sanofi, Santen, Recipharm, Tjoapack, MIT and the European Medicines Verification Organisation (EMVO).
“There is tremendous value in connecting companies and trade partners together in an educational forum, allowing everyone to equally learn from collective wisdom. This year, NEXUS truly showcased the power of the network in the pharmaceutical supply chain – demonstrated through inspirational keynotes, dynamic breakout and roundtable discussions, and high attendee engagement during the networking sessions,” said Shabbir Dahod, president and CEO, TraceLink.
“As serialization deadlines fall into place, now is the time to leverage the foundation of an integrated network to enhance real-time communication and information exchange between all of the partners in the supply chain. By enabling the flow of serialization data between over 260,000 trade partners on our network, TraceLink is the only provider that can deliver the next step of capabilities by taking information and moving it end-to-end across the supply chain."
NEXUS 17 attendees also responded to questions about serialization preparation, challenges and trade partner readiness, indicating the following:
Related News
-
News Pharmaceutical Supply Chain People Moves
The latest appointments, promotions, and structural changes across the pharmaceutical supply chain.
-
News Merck KGaA to buy US biotech SpringWorks for US$3.9 billion
The German multinational pharmaceutical company Merck KGaA have signed a deal to buy US biotech company SpringWorks Therapeutics at an equity value of US$3.9 billion in a move to add rare cancer therapeutics to their pipelines.
-
News Cassava Sciences halts Alzheimer's drug trial after limited progress
Cassava Sciences have drawn a close to their investigations and development of the drug simufilam, which they intended to be used for the treatment of Alzheimer’s disease.
-
News US FDA adds haemodialysis bloodlines to devices shortage list
On March 14, 2025, the US FDA published an open letter to healthcare providers citing continuing supply disruptions of haemodialysis bloodlines, an essential component of dialysis machines.
-
News Vertex Pharmaceuticals stock jumps as FDA approves non-opioid painkiller
UK-based Vertex Pharmaceuticals saw their stock shares soar as the US FDA signed off on the non-opioid painkiller Journavx, also known as suzetrigine, for patients with moderate to severe acute pain, caused by surgery, accidents, or injuries.
-
News Lessons from CPHI Milan 2024: Sunny Intervals for Pharma Manufacturing?
As the 2024 CPHI conference wrapped up in Milan, we caught up with L.E.K. Consulting – a global strategy consulting firm with deep expertise in pharma manufacturing – to discuss evolving market perspectives and business outlook. -
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Drug prices agreed upon as part of the US Inflation Reduction Act
The Inflation Reduction Act brought into constitution by the Biden administation in 2022, which proposed a drug price negotiation between the government and pharmaceutical companies, has reached it's first agreement.